Open-label study of Belimumab plus standard therapy in Chinese Pediatric participants with active Systemic Lupus Erythematosus (SLE)

Trial Identifier: 213560
Sponsor: GlaxoSmithKline
Collaborator:
NA
Start Date: October 2021
Primary Completion Date: May 2024
Study Completion Date: August 2024
Condition: Lupus

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
CHINA Beijing, CHINA, 100045
CHINA Changchun, CHINA, 130021
CHINA Changsha, CHINA, 410007
CHINA Hangzhou, CHINA, 310052
CHINA Nanjing, CHINA, 210011
CHINA Shanghai, CHINA, 361006
CHINA Suzhou, CHINA, 215007
CHINA Xi'an, CHINA, 710054